The company behind popular brands like Tylenol and Band-Aid delivered financial results that surpassed Wall Street expectations for the final quarter of last year, while simultaneously revealing plans to reduce its global workforce as part of a massive corporate merger.
Kenvue’s leadership team has given the green light to restructure operations, which will eliminate approximately 3.5% of jobs across the company’s worldwide operations. With roughly 22,000 workers employed as of the previous year, this translates to significant workforce reductions.
The pharmaceutical giant is moving forward with its acquisition by Kimberly-Clark, the tissue and diaper manufacturer, in a deal valued at over $40 billion announced last November. This transaction would combine major household brands including Band-Aid with Kleenex and Huggies under one corporate umbrella.
Company officials anticipate the merger will reach completion during the latter half of 2026.
Financial performance during the most recent quarter demonstrated a notable recovery for the healthcare company, driven by strong performance in both its personal care and essential health product lines.
“We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales,” said CEO Kirk Perry.
The company’s primary division, which includes pain relief medications like Tylenol and allergy treatments such as Benadryl, generated $1.59 billion in revenue during the quarter. This represented a 1.5% increase and exceeded analyst projections of $1.52 billion.
Management reported that consumer demand and market share trends for Tylenol showed improvement throughout December.
Meanwhile, the essential health division, featuring oral care products like Listerine and first-aid supplies including Band-Aid, produced $1.15 billion in quarterly revenue. This marked a 6.1% year-over-year growth rate, surpassing the average analyst forecast of $1.12 billion.
Overall company revenue for the fourth quarter climbed 3.2% to reach $3.78 billion, beating the consensus estimate of $3.68 billion among financial analysts.
Per-share earnings on an adjusted basis came in at 27 cents, exceeding analyst expectations of 22 cents per share.
The workforce reduction initiative is projected to generate approximately $250 million in pre-tax restructuring costs and related expenses during 2026, according to company statements.
